Cybin announces grant of european patent protecting its proprietary deuterated programs

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the european patent office (“ep”) has granted a patent protecting cybin's proprietary deuterated psilocybin analog and n, n-dimethyltryptamine (“dmt”) programs. ep patent no. 4,031,529 provides composition of matter prote.
CYBN Ratings Summary
CYBN Quant Ranking